To embed, copy and paste the code into your website or blog:
Citing concerns about growing consolidation, reduced competition, and increasing prices, President Biden issued on July 9, 2021 a sweeping Executive Order containing 72 initiatives to address competition concerns in a number of industries, including pharmaceuticals, biotech, and healthcare.
In his remarks at the signing of the July 9, 2021 Executive Order, President Biden focused on three specific initiatives, the first of which relates to lowering prescription drug prices. Americans are paying too much for prescription drugs and healthcare services far more than the prices paid in other countries, the Executive Order declares.
The Executive Order simultaneously backs legislative proposals to address drug prices, and directs agencies to take specific action designed to facilitate pharmaceutical competition. The Executive Order thus advances a focus on competition in the pharmaceutical industry, from both the legisla
United-states
Canada
White-house
District-of-columbia
Americans
American
Nancy-pelosi
Human-services
Drug-administration
Directives-to-health
Biden-administration
White-case-pharmaceuticals-healthcare-industry-group